WO2009034558A3 - Rhein or diacerein compositions - Google Patents

Rhein or diacerein compositions Download PDF

Info

Publication number
WO2009034558A3
WO2009034558A3 PCT/IB2008/053716 IB2008053716W WO2009034558A3 WO 2009034558 A3 WO2009034558 A3 WO 2009034558A3 IB 2008053716 W IB2008053716 W IB 2008053716W WO 2009034558 A3 WO2009034558 A3 WO 2009034558A3
Authority
WO
WIPO (PCT)
Prior art keywords
rhein
compositions
diacerein
diacerein compositions
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/053716
Other languages
French (fr)
Other versions
WO2009034558A2 (en
Inventor
Rahul Dabre
Girish Kumar Jain
Cyril Estanove
François PRUVOST
Roshanlal Sandal
Prashant Mandaogade
Premchand Nakhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Research Centre
Original Assignee
Wockhardt Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Centre filed Critical Wockhardt Research Centre
Priority to PL08807649T priority Critical patent/PL2224914T3/en
Priority to ES08807649.2T priority patent/ES2560899T3/en
Priority to US12/677,532 priority patent/US8821924B2/en
Priority to EP08807649.2A priority patent/EP2224914B1/en
Publication of WO2009034558A2 publication Critical patent/WO2009034558A2/en
Anticipated expiration legal-status Critical
Publication of WO2009034558A3 publication Critical patent/WO2009034558A3/en
Priority to US14/246,055 priority patent/US20140302126A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions.
PCT/IB2008/053716 2007-09-14 2008-09-13 Rhein or diacerein compositions Ceased WO2009034558A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL08807649T PL2224914T3 (en) 2007-09-14 2008-09-13 Diacerein compositions
ES08807649.2T ES2560899T3 (en) 2007-09-14 2008-09-13 Diacerein Compositions
US12/677,532 US8821924B2 (en) 2007-09-14 2008-09-13 Rhein or diacerein compositions
EP08807649.2A EP2224914B1 (en) 2007-09-14 2008-09-13 Diacerein compositions
US14/246,055 US20140302126A1 (en) 2007-09-14 2014-04-05 Rhein or diacerein compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1766MU2007 2007-09-14
IN1766/MUM/2007 2007-09-14
IN1897MU2007 2007-09-27
IN1896MU2007 2007-09-27
IN1897/MUM/2007 2007-09-27
IN1896/MUM/2007 2007-09-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/677,532 A-371-Of-International US8821924B2 (en) 2007-09-14 2008-09-13 Rhein or diacerein compositions
US14/246,055 Continuation US20140302126A1 (en) 2007-09-14 2014-04-05 Rhein or diacerein compositions

Publications (2)

Publication Number Publication Date
WO2009034558A2 WO2009034558A2 (en) 2009-03-19
WO2009034558A3 true WO2009034558A3 (en) 2010-04-22

Family

ID=40452656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/053716 Ceased WO2009034558A2 (en) 2007-09-14 2008-09-13 Rhein or diacerein compositions

Country Status (5)

Country Link
US (2) US8821924B2 (en)
EP (5) EP2471515A3 (en)
ES (1) ES2560899T3 (en)
PL (1) PL2224914T3 (en)
WO (1) WO2009034558A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429236B (en) * 2011-03-11 2016-09-21 安成生物科技股份有限公司 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371431A2 (en) * 1988-11-28 1990-06-06 Vectorpharma International S.P.A. Supported drugs with increased dissolution rate, and a process for their preparation
US5952383A (en) * 1996-07-04 1999-09-14 Negma-Steba International Development N.V. Pharmaceutical composition for oral delivery
US6124358A (en) * 1996-12-23 2000-09-26 Mazal Pharmaceutique (Sarl) Pharmaceutical composition containing rhein or diacerhein with improved bioavailability

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569469A (en) 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IT1189097B (en) 1986-05-02 1988-01-28 Proter Spa DIACETHYLREIN SALTS AND THEIR THERAPEUTIC USE IN THE TREATMENT OF ARTHROSIS
IT1200217B (en) 1986-09-30 1989-01-05 Valducci Roberto MEMBRANE FOR PHARMACEUTICAL AND INDUSTRIAL USE
IT1197316B (en) 1986-10-01 1988-11-30 Proter Spa GALENIC FORMULATION FOR ORAL USE OF REINA DERIVATIVES SLOWLY RELEASED FOR THERAPEUTIC USE
IT1230566B (en) 1988-10-17 1991-10-28 Vectorpharma Int LITTLE SOLUBLE DRUGS SUPPORTED ON POLYMERIC SUBSTANCES IN A FORM THAT WILL INCREASE THE DISSOLUTION SPEED
IT1241417B (en) 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
YU48263B (en) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT
JP3707798B2 (en) 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム Intraoral drug delivery system
WO1997044014A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
DE69934505T2 (en) 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. IN THE MUND DISSOLVING TABLET CONTAINING A BENZIMIDAZOLE
DE69905380T2 (en) 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde PHARMACEUTICAL COMPOSITIONS WITH QUICK RELEASE OF ACTIVE SUBSTANCES
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20050163852A1 (en) * 2002-03-07 2005-07-28 Massimo Bresciani Process for loading and thermodynamically activating drungs on polymers by means of supercritical fluids
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
CN103494766A (en) 2004-11-24 2014-01-08 特瓦制药工业有限公司 Rasagiline orally disintegrating compositions
PL385455A1 (en) 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Oral disintegrating pharmaceutical tablet of olanzapine preparations
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
TWI383809B (en) 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
CN1748675A (en) * 2005-07-11 2006-03-22 丛晓东 Composition of rheinic acid compounds and preparing method and use for treating diabetes
JP2009523784A (en) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド Stable pharmaceutical preparation of acid labile compound and method for producing the same
US20070196494A1 (en) 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CN101032476A (en) * 2006-03-10 2007-09-12 刘德海 Medical combination including rhein or diacetylrhein and the preparing method thereof
CN100475201C (en) * 2007-03-19 2009-04-08 上海慈瑞医药科技有限公司 Preparation method of diacetyl rhein sustained-release tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371431A2 (en) * 1988-11-28 1990-06-06 Vectorpharma International S.P.A. Supported drugs with increased dissolution rate, and a process for their preparation
US5952383A (en) * 1996-07-04 1999-09-14 Negma-Steba International Development N.V. Pharmaceutical composition for oral delivery
US6124358A (en) * 1996-12-23 2000-09-26 Mazal Pharmaceutique (Sarl) Pharmaceutical composition containing rhein or diacerhein with improved bioavailability

Also Published As

Publication number Publication date
WO2009034558A2 (en) 2009-03-19
PL2224914T3 (en) 2015-11-30
US20120070492A1 (en) 2012-03-22
EP2224914B1 (en) 2015-01-21
EP2471516A2 (en) 2012-07-04
EP2471515A2 (en) 2012-07-04
ES2560899T3 (en) 2016-02-23
EP2224914A2 (en) 2010-09-08
EP2471517A2 (en) 2012-07-04
US20140302126A1 (en) 2014-10-09
EP2471517A3 (en) 2012-12-26
EP2471516A3 (en) 2012-12-26
EP2471515A3 (en) 2012-12-26
US8821924B2 (en) 2014-09-02
EP3207921A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
NL300871I2 (en) ixazomib and pharmaceutically acceptable salts and esters thereof, such as ixazomib citrate
HK1198359A1 (en) Carrier-linked treprostinil prodrugs
IL209054A0 (en) Solid pharmaceutical formulations comprising bibw 2992
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
WO2008070268A3 (en) Pharmaceutical compositions
WO2013057570A3 (en) Acrylic polymer formulations
WO2009118589A3 (en) Orally disintegrating compositions of rhein or diacerein
WO2009100995A3 (en) Storage-stable product systems for premix formulations
WO2009091898A3 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2010138598A3 (en) Lxr modulators
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
WO2010141693A3 (en) Borinic compositions
IN2012DN03807A (en)
WO2013055684A8 (en) Rasagiline citramide
WO2014078309A8 (en) Cannabinoid receptor mediating compounds
WO2009133455A3 (en) Pharmaceutical composition of clodipogrel
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
PH12013501055A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
PH12013501054A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
WO2011139253A3 (en) Pharmaceutical compositions comprising ceftibuten
EP2634182B8 (en) Method for preparing 1,3,5-trioxane
EP2634183B8 (en) Method for preparing 1,3,5-trioxane
WO2012026907A3 (en) Cefpodoxime proxetil formulations
WO2009016608A3 (en) Pharmaceutical compositions of fenofibrate

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008807649

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12677532

Country of ref document: US